Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2019-08-25 Annual Report
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Appendix 4E and 2019 Annual Report 62 pages 1.3MB
Annual Report Classification · 100% confidence The document is titled 'Prescient Therapeutics Limited Annual Report - 30 June 2019' and contains detailed financial statements, including profit or loss, financial position, cash flows, notes to the financial statements, and auditor's report. It covers the full fiscal year ended 30 June 2019 and includes comprehensive management commentary, chairman's letter, review of operations, and detailed financial data. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial statements and detailed operational review confirms this is the official yearly report covering company activity and full financial performance, which matches the definition of an Annual Report (10-K). FY 2019
2019-08-25 English
Appendix 4G and Corporate Governance Statement 23 pages 412.0KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references the ASX Listing Rules, specifically Listing Rule 4.7.3 and 4.10.3, which relate to corporate governance disclosures. It includes a key to disclosures against the Corporate Governance Council Principles and Recommendations and mentions that the corporate governance statement is lodged with ASX alongside the annual report. The content focuses on governance practices, board and management roles, and compliance with governance recommendations. There is no financial data, earnings information, or audit content. The document is a regulatory filing related to corporate governance disclosures required by the ASX but is not the annual report itself or a governance report in the sense of internal governance rules. It is a formal regulatory filing to comply with ASX requirements for corporate governance disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-08-25 English
Securities Trading Policy 6 pages 175.8KB
Governance Information Classification · 95% confidence The document is a detailed Securities Trading Policy for Prescient Therapeutics Limited. It outlines rules and procedures for directors, officers, and employees regarding insider trading, pre-dealing approvals, closed periods, and exceptions. It is a governance-related document focused on internal rules and compliance with securities laws, rather than a financial report, announcement, or regulatory filing. There is no financial data, earnings information, or report publication mentioned. The content fits the definition of Governance Information (CGR) as it details the company's internal rules and governance practices related to securities trading.
2019-08-21 English
June 2019 Appendix 4C - Quarterly 9 pages 204.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'June 2019 Quarterly Update and Appendix 4C' from Prescient Therapeutics Limited. It includes a financial update with cash reserves, clinical progress, business development, and a detailed Appendix 4C which is a quarterly report for entities subject to Listing Rule 4.7B. The Appendix 4C contains consolidated statement of cash flows and other financial data for the quarter ended 30 June 2019. The document is about quarterly financial results and operational highlights, including substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2019
2019-07-23 English
PTX Initiates Phase 1b Clinical Trial for PTX-100 4 pages 162.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing the initiation of a Phase 1b clinical trial for a new anti-cancer drug by Prescient Therapeutics. It contains detailed information about the clinical trial design, drug mechanism, lead investigator, and company background. There are no financial statements, earnings data, or regulatory compliance filings. The content is a corporate announcement about a clinical trial start, which is a typical type of regulatory announcement or general company update. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a clinical trial start. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-07-10 English
Ceasing to be a substantial holder 2 pages 78.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001, Section 671B. It details changes in substantial shareholding, including dates and parties involved. This type of filing is a notification of changes in major share ownership levels, specifically when a holder ceases to be substantial. It is not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2019-06-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.